Mitochondrial Damage-Induced Innate Immune Activation in Vascular Smooth Muscle Cells Promotes Chronic Kidney Disease-Associated Plaque Vulnerability.
Mitochondrial Damage-Induced Innate Immune Activation in Vascular Smooth Muscle Cells Promotes Chronic Kidney Disease-Associated Plaque Vulnerability.
复制标题
线粒体损伤——血管平滑肌细胞中诱导的先天免疫激活促进慢性肾脏病——相关的斑块脆弱性
DOI:
10.1002/advs.202002738
复制
发表时间:
2021-03
期刊:
影响因子:
--
通讯作者:
Zhao J
中科院分区:
文献类型:
--
作者:
Bi X;Du C;Wang X;Wang XY;Han W;Wang Y;Qiao Y;Zhu Y;Ran L;Liu Y;Xiong J;Huang Y;Liu M;Liu C;Zeng C;Wang J;Yang K;Zhao J
Chronic kidney disease (CKD) is associated with accelerated atherosclerosis progression and high incidence of cardiovascular events, hinting that atherosclerotic plaques in CKD may be vulnerable. However, its cause and mechanism remain obscure. Here, it is shown that apolipoprotein E‐deficient (ApoE−/−) mouse with CKD (CKD/ApoE−/− mouse) is a useful model for investigating the pathogenesis of plaque vulnerability, and premature senescence and phenotypic switching of vascular smooth muscle cells (VSMCs) contributes to CKD‐associated plaque vulnerability. Subsequently, VSMC phenotypes in patients with CKD and CKD/ApoE−/− mice are comprehensively investigated. Using multi‐omics analysis and targeted and VSMC‐specific gene knockout mice, VSMCs are identified as both type‐I‐interferon (IFN‐I)‐responsive and IFN‐I‐productive cells. Mechanistically, mitochondrial damage resulting from CKD‐induced oxidative stress primes the cyclic GMP‐AMP synthase‐stimulator of interferon genes (cGAS‐STING) pathway to trigger IFN‐I response in VSMCs. Enhanced IFN‐I response then induces VSMC premature senescence and phenotypic switching in an autocrine/paracrine manner, resulting in the loss of fibrous cap VSMCs and fibrous cap thinning. Conversely, blocking IFN‐I response remarkably attenuates CKD‐associated plaque vulnerability. These findings reveal that IFN‐I response in VSMCs through immune sensing of mitochondrial damage is essential for the pathogenesis of CKD‐associated plaque vulnerability. Mitigating IFN‐I response may hold promise for the treatment of CKD‐associated cardiovascular diseases.
登录
查看更多内容
DOI:
10.1056/nejmoa1312625
发表时间:
2014-08-07
期刊:
The New England journal of medicine
影响因子:
--
作者:
Liu Y;Jesus AA;Marrero B;Yang D;Ramsey SE;Sanchez GAM;Tenbrock K;Wittkowski H;Jones OY;Kuehn HS;Lee CR;DiMattia MA;Cowen EW;Gonzalez B;Palmer I;DiGiovanna JJ;Biancotto A;Kim H;Tsai WL;Trier AM;Huang Y;Stone DL;Hill S;Kim HJ;St Hilaire C;Gurprasad S;Plass N;Chapelle D;Horkayne-Szakaly I;Foell D;Barysenka A;Candotti F;Holland SM;Hughes JD;Mehmet H;Issekutz AC;Raffeld M;McElwee J;Fontana JR;Minniti CP;Moir S;Kastner DL;Gadina M;Steven AC;Wingfield PT;Brooks SR;Rosenzweig SD;Fleisher TA;Deng Z;Boehm M;Paller AS;Goldbach-Mansky R
通讯作者:
Goldbach-Mansky R
影响因子:
168.9
作者:
Jha, Vivekanand;Garcia-Garcia, Guillermo;Yang, Chih-Wei
通讯作者:
Yang, Chih-Wei
DOI:
10.1084/jem.20180139
发表时间:
2018-05-07
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Li T;Chen ZJ
通讯作者:
Chen ZJ
影响因子:
10.8
作者:
Bauriedel, G;Hutter, R;Lüderitz, B
通讯作者:
Lüderitz, B
DOI:
10.1016/s0022-5320(61)80002-6
发表时间:
1961-01-01
期刊:
JOURNAL OF ULTRASTRUCTURE RESEARCH
影响因子:
--
作者:
KARRER, HE
通讯作者:
KARRER, HE